Across TCGA pan-cancer cohorts, RASA4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RASA4 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher RASA4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RASA4 expression acts as an unfavorable survival marker.
COAD and BLCA are the cancer types where RASA4 Mutation most reproducibly stratifies survival.